Auditory and Visual Toxicity During Deferoxamine Therapy in Transfusion-Dependent Patients
Authors:
- Der-Cherng LiangDLDer-Cherng Liang
- Hung-Ching LinHLHung-Ching Lin
- Shu-Yun ChengSCShu-Yun Cheng
- Lee-Jen ChenLCLee-Jen Chen
- Hsi-Che LiuHLHsi-Che Liu
- 1 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 27 (12) , 651-653
Abstract
Deferoxamine is a chelating agent that has extended the life expectancy of patients with thalassemia. In the 1980s, many investigators reported otologic and visual toxicity caused by deferoxamine. In July 1999 and 2 years later, the authors performed audiologic and ophthalmologic assessments in 30 transfusion-dependent patients receiving deferoxamine therapy (40-50 mg/kg per dose, subcutaneously for 8-10 hours, 4-7 days per week). In 1999, six patients (20%) had deferoxamine-related hearing impairment (>25 dB), all at high frequencies. Because the authors believed the benefits of chelation therapy outweighed the risk of ototoxicity, the dose of deferoxamine was not reduced. Two years later, the hearing impairment had not progressed in any of the patients. There was no association between ototoxicity and ferritin level. No patients had abnormalities of visual acuity or funduscopy in either 1999 or 2001. Based on this experience, deferoxamine at doses lower than 50 mg/kg/d was safe for the eyes and slightly toxic to the ears. The ototoxicity probably relates to individual susceptibility. Regular monitoring of auditory function and close follow-up of abnormal findings are recommended. According to this limited experience, reducing the dose or withdrawing deferoxamine might not be necessary if the hearing loss is stable in the face of ferritin levels above 2,000 ng/mL. Because of the relatively small patient numbers, more data are needed to confirm these conclusions.Keywords
This publication has 20 references indexed in Scilit:
- Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatmentPharmacological Research, 2000
- Ototoxicity in Hemoglobinopathy Patients Chelated with DesferrioxamineJournal of Pediatric Hematology/Oncology, 1996
- Deferoxamine-associated Retinopathy After Subcutaneous InjectionAmerican Journal of Ophthalmology, 1994
- Visual function during long-term desferrioxamine treatmentThe Lancet, 1993
- Vision and hearing during deferoxamine therapyThe Journal of Pediatrics, 1990
- Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosageBritish Journal of Haematology, 1989
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Auditory Involvement in Thalassemia MajorActa Haematologica, 1979
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977
- Iron Excretion in Thalassaemia Major After Administration of Chelating AgentsBMJ, 1962